These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3472701)

  • 1. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy.
    Relling MV; Crom WR; Pieper JA; Cupit GC; Rivera GK; Evans WE
    Clin Pharmacol Ther; 1987 Jun; 41(6):651-60. PubMed ID: 3472701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous administration of multiple model substrates to assess hepatic drug clearance.
    Crom WR; Webster SL; Bobo L; Teresi ME; Relling MV; Evans WE
    Clin Pharmacol Ther; 1987 Jun; 41(6):645-50. PubMed ID: 3581648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neurotrauma on hepatic drug clearance.
    Boucher BA; Kuhl DA; Fabian TC; Robertson JT
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):487-97. PubMed ID: 1934861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.
    Crom WR; Relling MV; Christensen ML; Rivera GK; Evans WE
    Clin Pharmacol Ther; 1991 Aug; 50(2):132-40. PubMed ID: 1868674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver volume as a determinant of drug clearance in children and adolescents.
    Murry DJ; Crom WR; Reddick WE; Bhargava R; Evans WE
    Drug Metab Dispos; 1995 Oct; 23(10):1110-6. PubMed ID: 8654200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced hepatic drug clearance in patients with cystic fibrosis.
    Kearns GL; Mallory GB; Crom WR; Evans WE
    J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam.
    Abernethy DR; Greenblatt DJ; Eshelman FN; Shader RI
    Clin Pharmacol Ther; 1984 Feb; 35(2):188-92. PubMed ID: 6319067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.
    Roberts CJ; Jackson L; Halliwell M; Branch RA
    Br J Clin Pharmacol; 1976 Oct; 3(5):907-13. PubMed ID: 973986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine.
    Abernethy DR; Greenblatt DJ; Divoll M; Ameer B; Shader RI
    J Pharmacol Exp Ther; 1983 Mar; 224(3):508-13. PubMed ID: 6827475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
    Andersen V; Sonne J; Larsen S
    Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsomal enzymes in patients with acute leukemia as determined by plasma half-life of antipyrine.
    Higuchi T; Nakamura T; Uchino H
    Cancer Chemother Pharmacol; 1980; 5(1):55-9. PubMed ID: 6936094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1977 Apr; 21(4):470-81. PubMed ID: 849678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination.
    Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1979 Jul; 26(1):16-20. PubMed ID: 445957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of experimental hemorrhagic shock on hepatic drug elimination.
    DiPiro JT; Hooker KD; Sherman JC; Gaines MG; Wynn JJ
    Crit Care Med; 1992 Jun; 20(6):810-5. PubMed ID: 1597036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity.
    Williams SJ; Farrell GC
    Hepatology; 1989 Aug; 10(2):192-7. PubMed ID: 2744731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of isolated hepatic ischemia on organic anion clearance and oxidative metabolism.
    Minard G; Bynoe R; Wood GC; Fabian TC; Croce M; Kudsk KA
    J Trauma; 1992 Apr; 32(4):514-8; discussion 518-9. PubMed ID: 1569625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic oral cimetidine on apparent liver blood flow and hepatic microsomal enzyme activity in man.
    Daneshmend TK; Ene MD; Parker G; Roberts CJ
    Gut; 1984 Feb; 25(2):125-8. PubMed ID: 6693040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.